By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their viral loads to undetectable levels and then come off the medicine.

The clearance rates for those coinfected with HIV and hepatitis C virus (HCV) are still higher than those with HCV alone.

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Couples that were made up of 2 transgender women were less likely to contract HIV compared with couples that were made up of ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...

For more than 20 years, Harvard infectious disease specialist Roger Shapiro has fought HIV on the ground in Botswana, where ...

When it comes to HIV prevention, the U.S. Supreme Court appeared to back up the task force with its July 11 ruling in Kennedy ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

The HIV and Faith conference is an event that will feature the premiere of the documentary 'Disrupting Stigma with Disrupting ...

This August, First Baptist Church in Austin hosts a memorial that renders that faith tangible.